Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 15 | 38 | 39 | 37 | 35 |
| Accounts receivable | 2 | 237 | -227 | 17 | 50 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 202 | N/A |
| Other Working Capital | 416 | 175 | 294 | 59 | 419 |
| Other Operating Activity | -4,613 | -3,697 | -3,191 | -1,744 | -2,503 |
| Operating Cash Flow | $-4,181 | $-3,247 | $-3,086 | $-1,429 | $-1,999 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | 0 | 0 | -3 | -3 |
| Other Investing Activity | 8 | 0 | 0 | -136 | 0 |
| Investing Cash Flow | $8 | $0 | $0 | $-138 | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -25 | -25 | -25 | -25 | -25 |
| Common Stock Issued | 0 | 23,012 | 0 | N/A | N/A |
| Other Financing Activity | 137 | -982 | 100 | 98 | 279 |
| Financing Cash Flow | $111 | $22,004 | $75 | $72 | $254 |
| Exchange Rate Effect | 317 | -112 | -115 | 198 | -191 |
| Beginning Cash Position | 30,304 | 11,660 | 14,786 | 16,083 | 18,021 |
| End Cash Position | 26,560 | 30,304 | 11,660 | 14,786 | 16,083 |
| Net Cash Flow | $-4,061 | $18,757 | $-3,011 | $-1,495 | $-1,748 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,181 | -3,247 | -3,086 | -1,429 | -1,999 |
| Capital Expenditure | N/A | N/A | N/A | -138 | N/A |
| Free Cash Flow | -4,181 | -3,247 | -3,086 | -1,568 | -1,999 |